Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Solid Tumors 1Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Multiple Myeloma 1Insulin-Like Growth Factor I, Resistance To 1Advanced Solid Tumors 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × dalotuzumab × Clear all
NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
81 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡